Application Note: The Agilent xCELLigence RTCA CardioECR System
15 March 2023

In this application note, Agilent introduces the xCELLigence RTCA CardioECR system, a dual-mode instrument that includes directed electrical pacing of hiPSC-CMs as well as simultaneous monitoring of hiPSC-CM viability, contraction, and FP in real-time. The multiplexed evaluation of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) using the CardioECR system allows for a suitable assay platform to predict drug-induced proarrhythmia, contractile liability, and chronic toxicity of drugs under development.